Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound ...
- Reuters Citing Conf Call
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage...
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month I...
https://www.youtube.com/watch?v=GFGmukrxZ7Y
https://www.youtube.com/watch?v=GFGmukrxZ7Y
BMO Capital analyst Evan Seigerman maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $930 to...
Eli Lilly and Company (NYSE:LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of el...
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump ...
